Rationale: Protein S-nitros(yl)ation (SNO) has been implicated as an essential mediator of nitric oxide-dependent cardioprotection. Compared with males, female hearts exhibit higher baseline levels of protein SNO and associated with this, reduced susceptibility to myocardial ischemia-reperfusion injury. Female hearts also exhibit enhanced S-nitrosoglutathione reductase (GSNO-R) activity, which would typically favor decreased SNO levels as GSNO-R mediates SNO catabolism.
R eversible cysteine oxidation plays a critical role in reducing myocardial injury from ischemia-reperfusion (I/R), which is a major cause of death among males and females in the United States. Nitric oxide (NO) has also been shown to be an important component of cardioprotection. [1] [2] [3] Taken together, this suggests a potential role for protein S-nitros(yl)ation (SNO) in cardioprotection. 4, 5 SNO is a specific and reversible cysteine thiol modification resulting from the covalent attachment of a NO moiety, with diverse effects on protein activity, stability, protein-protein interactions, and cellular localization. 4 Myocardial SNO homeostasis is primarily mediated by the actions of constitutive NO synthase (NOS) isoforms, eNOS (endothelial NOS) and neuronal NOS, and via S-nitrosoglutathione reductase (GSNO-R). 6 Originally characterized as an alcohol dehydrogenase (ADH5), GSNO-R also functions as a reductase that metabolizes S-nitrosoglutathione (GSNO), 7 which is an important bioavailable reserve for NO in the cell that remains in equilibrium with SNO proteins. GSNO-R also acts as a formaldehyde dehydrogenase (FDH) by catalyzing the oxidation of S-hydroxymethylglutathione, 8 the spontaneous reaction product of formaldehyde and glutathione. Importantly, we and others have demonstrated that myocardial SNO protein levels increase with various cardioprotective stimuli, [9] [10] [11] [12] [13] [14] [15] [16] [17] thus implicating SNO as a critical stress response that serves to acutely protect the heart against I/R injury. Chronic upregulation of protein SNO levels, as occurs with the genetic deletion of GSNO-R, is also associated with protection in male hearts. 18, 19 Recent findings from our group further suggest that protein SNO plays a key role in protecting the female heart from I/R injury. 17, 20 Premenopausal women have a reduced risk for developing cardiovascular disease compared with age-matched men. [21] [22] [23] Preclinical studies from our group and others have demonstrated an intrinsic, NO-dependent cardioprotective mechanism in female hearts, with females exhibiting enhanced functional recovery and smaller infarcts versus males. 20, [24] [25] [26] Prior work has also shown that protection from I/R injury is lost in female hearts after ovariectomy, 26, 27 suggesting a role for estrogen. In further support of this NO-dependent protection, we recently demonstrated that female hearts exhibit enhanced PI3K-Akt signaling, increased eNOS expression and activation, and higher protein SNO levels compared with male hearts. 17, 20 We also found that GSNO-R activity was significantly enhanced in female hearts at baseline versus males, 17, 20 which should favor reduced SNO levels in female hearts. This finding suggests that GSNO-R may play a protective role in female hearts, perhaps by mitigating the potential for excessive protein SNO accumulation and nitrosative stress. Indeed prior studies demonstrate GSNO-R-mediated protection in sepsis and pulmonary hypertension. 6, 28 However, little is known with regard to the role of GSNO-R in female myocardial I/R injury.
In the current study, we used a specific and potent GSNO-R inhibitor (N6022) to assess the role of GSNO-R in I/R injury in male and female hearts. 29 N6022 is currently in clinical trials for the treatment of asthma and cystic fibrosis and has been well tolerated in humans and animals. 7 We found that GSNO-R inhibition or genetic deletion, led to sex-disparate effects using ex vivo and in vivo models of myocardial I/R injury, yielding protective effects in males, but unexpectedly worsening injury in females. The beneficial and injurious effects of GSNO-R inhibition resulted, in part, from differential changes in myocardial protein SNO signaling, reactive oxygen species (ROS) production, and formaldehyde accumulation.
Methods
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Results

Acute GSNO-R Inhibition Alters the Myocardial Response to I/R Injury
The genetic deletion of GSNO-R is known to be protective in male hearts subjected to in vivo I/R injury, 18, 19 but female hearts have not been examined. Thus, we sought to determine the effect of GSNO-R inhibition on the response to I/R 
Novelty and Significance
What Is Known?
• The enzyme S-nitrosoglutathione reductase (GSNO-R) indirectly regulates the cellular levels of protein S-nitros(yl)ation (SNO) and formaldehyde.
• Increased SNO protein levels and the genetic deletion of GSNO-R have been shown to reduce infarct size in male hearts subjected to ischemia-reperfusion injury (I/R).
• In comparison with male hearts, female hearts have increased SNO protein levels and GSNO-R activity, and exhibit endogenous, nitric oxide-dependent protection from I/R injury.
What New Information Does this Article Contribute?
• Inhibition or genetic deletion of GSNO-R led to sex-disparate effects on myocardial I/R injury.
• In male hearts, the loss of GSNO-R reduced I/R injury, in part, through increased SNO protein levels and decreased production of reactive oxygen species.
• In female hearts, the loss of GSNO-R exacerbated I/R injury, in part, through increased formaldehyde production.
Sex-dependent differences in myocardial pathophysiology are emerging as a critical area of research. In this study, we examined the role in GSNO-R in male and female hearts during I/R injury. We found that genetic deletion of GSNO-R or inhibition of the enzyme using a specific and potent inhibitor (N6022), led to sex-disparate effects in both in vivo and ex vivo models of myocardial I/R injury. In males, loss of GSNO-R reduced damage, but in females, cell death in the myocardium was increased. In male hearts, the loss of GSNO-R increased total SNO protein levels and reduced the postischemic production of reactive oxygen species, in part, through the SNO-induced modification of mitochondrial proteins. In female hearts, GSNO-R loss did not alter SNO protein levels but increased postischemic levels of formaldehyde. The Alda-1-induced activation of aldehyde dehydrogenase 2 to scavenge excess formaldehyde, rescued the injurious phenotype in female hearts lacking GSNO-R. These results identify formaldehyde as a novel mediator of myocardial I/R injury in female hearts and suggest that GSNO-R is an essential component of cardioprotection in females. These findings emphasize that different therapeutic strategies may be required to treat ischemic heart disease in males and females.
injury in female hearts. To avoid compensatory adaptation with the use of genetically modified mice, we initially used the GSNO-R inhibitor N6022 to acutely block enzyme activity. 29 We used a Langendorff-perfused heart model of I/R injury to avoid the confounding effects of circulating hormones (ie, estrogen) and GSNO on the response to I/R injury. Sexdependent cardioprotection was assessed in C57Bl/6J wildtype (WT) mouse hearts under control conditions (ie, without N6022; Figure 1A ). Initial hemodynamic measurements indicated no differences in baseline left ventricular developed pressure or heart rate between WT male and female hearts (Online Table I ). After 20 minutes of global ischemia and 60 minutes of reperfusion, the contractile function was significantly impaired in male and female hearts, but postischemic functional recovery was significantly higher in female hearts ( Figure 1B ) and infarct size was reduced ( Figure 1C ).
Male and female WT hearts were also perfused with N6022 (100 nmol/L or 10 μmol/L) for 15 minutes before the onset of ischemia and for 5 minutes at the start of reperfusion ( Figure 1A ). Interestingly, baseline heart rate was significantly decreased in N6022-treated female hearts (Online Table I ); baseline cardiac function in male hearts was unaffected by N6022. After 20 minutes of ischemia and 60 minutes of reperfusion, male hearts exhibited a dose-dependent improvement in postischemic functional recovery with N6022 ( Figure 1D) ; infarct size showed a similar dose-dependent decrease with N6022 ( Figure 1E ). In female hearts, however, we found that GSNO-R inhibition abrogated sex-dependent protection and exacerbated injury, with female hearts exhibiting a dose-dependent decrease in postischemic functional recovery ( Figure 1F ) and increased infarct size ( Figure 1G ) with N6022. Treatment of WT male and female hearts with vehicle control (dimethyl sulfoxide) had no effect on the response to I/R injury (data not shown). These results suggest that GSNO-R is a requisite component for reducing I/R injury in females but not in males ( Figure 1H and 1I ).
Genetic Deletion of GSNO-R Alters the Myocardial Response to I/R Injury
Experiments were repeated in male and female mice with a genetic deletion of GSNO-R (GSNO-R −/− ; Online Figure I ). The phenotype of these mice has been well-characterized in previous studies. 6, 30 Initial hemodynamic measurements in Langendorff-perfused hearts revealed no differences in baseline left ventricular developed pressure or heart rate between male and female, WT and GSNO-R −/− mice (Online Table I ). A more thorough evaluation of baseline cardiac function using echocardiography revealed subtle differences in function between male and female, WT and GSNO-R −/− mice (Online Table II ), but these differences are not likely to impact the Figure 1 . S-nitrosoglutathione reductase (GSNO-R) inhibition induces protection in male hearts but exacerbates injury in female hearts. A, Hearts were perfused with or without the GSNO-R inhibitor N6022 for 15 min and then subjected to 20 min of ischemia and 120 min of reperfusion; N6022 was also present during the first 5 min of reperfusion. B, Postischemic functional recovery and (C) infarct size in control male and female WT hearts (n=12-13 hearts/group; *P<0.05 vs control male). D, Postischemic functional recovery and (E) infarct size in control and N6022-perfused male hearts (n=5-12 hearts/ group; *P<0.05 vs control male). F, Postischemic functional recovery and (G) infarct size in control and N6022-perfused female hearts (n=5-13 hearts/group; **P<0.05 vs control female). H, Percent change in postischemic functional recovery and (I) infarct size with 10 μmol/L N6022 treatment vs respective control male or female heart (n=6-7 hearts/group; *P<0.05 vs N6022-treated male). RPP indicates rate pressure product.
response to myocardial I/R injury. These results agree with findings in prior studies. 6, 30 Additionally, we did find a significant difference in weight, with male GSNO-R −/− mice weighing significantly less than male WT mice (Online Table II) .
Consistent with the effects of acute GSNO-R inhibition, we found that male GSNO-R −/− hearts showed a significant reduction in infarct size compared with WT using our Langendorff-perfused heart model of I/R injury ( Figure 2A ). Female GSNO-R −/− hearts, however, showed a substantial and significant increase in infarct size compared with WT ( Figure 2B ). As such, infarct size was reduced by >60% in male GSNO-R −/− hearts, whereas infarct size was increased by >30% in female GSNO-R −/− hearts (versus respective WT). Treatment of male and female GSNO-R −/− hearts with N6022 had no effect on the response to I/R injury (data not shown), confirming inhibitor specificity.
We also used an in vivo model of myocardial I/R injury to further examine the loss of GSNO-R. Male and female, WT and GSNO-R −/− mice were subjected to left anterior descending coronary artery occlusion for 45 minutes, followed by 24 hours of reperfusion. Consistent with our ex vivo results ( Figure 2A and 2B) and those reported previously, 18, 19 we found that male GSNO-R −/− hearts showed a significant reduction in infarct size compared with WT, whereas female GSNO-R −/− hearts showed a significant increase in infarct size compared with WT ( Figure 2C through 2H). Plasma cleaved troponin I (cTnI) levels were also decreased in male GSNO-R −/− versus WT and increased in female GSNO-R −/− versus WT ( Figure 2I and 2J), but these differences were not statistically significant. The area at risk was not different between groups ( Figure 2C and 2D).
GSNO-R Inhibition Increases Protein SNO Levels in Male Hearts
We examined the effect of GSNO-R inhibition on protein SNO levels at baseline and after I/R injury in male and female WT hearts using SNO-resin-assisted capture. 9, 15 To increase confidence, all reported SNO protein identifications were detected in at least 2 of 3 hearts per group. Consistent with the findings in our prior studies, 17, 20 WT female hearts exhibited nearly 2-fold more SNO protein identifications at baseline versus WT males (Figure 3A and 3B; Online Tables III and IV) . N6022 perfusion for 15 minutes substantially increased the number of SNO proteins identified in WT male hearts (Figure 3A and 3B; Online Table V) but had essentially no effect on total SNO protein identifications in WT female hearts (Figure 3A and 3B; Online Table VI) . After I/R injury, SNO protein levels decreased in all groups (Figure 3D and 3E; Online Tables VII through X), which is consistent with our previous study. However, the post-I/R decrease in SNO protein levels was partly impaired in N6022-treated male and female hearts, suggesting that N6022 does impact SNO protein levels in both male and female hearts.
We noted a strong association between the degree of I/Rdependent injury in both male and female, N6022-treated and nontreated hearts (Figure 1) , and preischemic levels of SNO at Cys39 of nicotinamide adenine dinucleotide (NADH) dehydrogenase subunit 3 (ND3). This cysteine has been shown to be a critical mitochondrial redox switch for NO-dependent protection from myocardial I/R injury by reducing ROS Figure 2 . Genetic deletion of S-nitrosoglutathione reductase (GSNO-R) induces protection in male hearts but exacerbates injury in female hearts. A and B, Infarct size from Langendorff-perfused male (A) and female (B) wild-type (WT; +/+) and GSNO-R −/− (−/−) hearts (n=6-8 hearts/ group; *P<0.05 vs male WT and **P<0.05 vs female WT). C through J, Area at risk (AAR; C and D), infarct size (% of AAR; E and F), infarct size (% of total ventricle; G and H), and plasma cleaved troponin I (cTnI) levels (I and J) from male and female WT and GSNO-R −/− hearts subjected to left anterior descending coronary artery occlusion surgery (n=8-9 mice/group; *P<0.05 vs male WT and **P<0.05 vs female WT).
generation from complex I that can occur via reverse electron transport. 31 Label-free peptide quantification was used to assess SNO-ND3 levels. We found that N6022 induced a significant increase in preischemic SNO-ND3 levels in male hearts, but significantly decreased preischemic SNO-ND3 levels in female hearts ( Figure 3C ). After reperfusion, we were no longer able to detect differences in SNO-ND3 levels ( Figure 3F ). These data suggest that enhanced SNO-ND3 may contribute to intrinsic protection in female hearts and N6022-mediated protection in male hearts.
GSNO-R Inhibition Suppresses Postischemic ROS Production
SNO-ND3 was reported to augment complex I-mediated ROS generation 32 ; therefore, we examined the impact of N6022 on postischemic H 2 O 2 production in male and female hearts. Consistent with prior studies, 17, 27 postischemic H 2 O 2 production was significantly decreased in control WT female hearts versus males ( Figure 4A and 4B), possibly via enhanced SNO-ND3 levels. Perfusion with N6022 before I/R injury substantially reduced postischemic H 2 O 2 production in WT male and as assessed via SNO-resin-assisted capture in tandem with liquid chromatography-tandem mass spectrometry (n=3 hearts/group; false discovery rate: 1%). Note: All SNO protein identifications were detected in at least 2 of 3 hearts/group; these numbers represent the total number of SNO proteins identified in each group, so statistics were not performed. C and F, SNOnicotinamide adenine dinucleotide (NADH) dehydrogenase subunit 3 (ND3) levels from control and N6022-treated male and female WT hearts at baseline (C) and post I/R (F) as assessed via spectral counting (n=3 hearts/group; *P<0.05 vs control male and **P<0.05 vs control female). female hearts (Figure 4A and 4B ). This decrease in postischemic ROS production is consistent with the N6022-mediated increase in SNO-ND3 levels in male hearts. However, since N6022 reduced SNO-ND3 levels in female hearts, the N6022-mediated reduction in postischemic ROS production likely occurs through a different mechanism.
N6022 Inhibits the GSNO-R-Mediated Metabolism of GSNO and Formaldehyde in the Heart
GSNO-R is reported to be the major enzyme responsible for the NADH-dependent reduction of GSNO in the heart and other organs. 6 To confirm GSNO-R inhibition with N6022, WT male and female hearts were perfused with or without N6022 and assayed for GSNO-R activity by monitoring NADH consumption using GSNO as a substrate. N6022 treatment completely blocked GSNO metabolism in WT male and female hearts ( Figure 5A and 5B). The assay was repeated with male and female heart homogenates from GSNO-R −/− mice treated with or without N6022, but GSNO-R activity was not detected. Additionally, because the liver shows high GSNO-R expression and activity, 6 we used liver homogenate as a positive control. Preincubation of mouse liver homogenate with N6022 for 15 minutes was sufficient to significantly inhibit GSNO metabolism (Online Figure IIA) . GSNO-R is also known to act as an FDH by metabolizing S-hydroxymethylglutathione. 8 We assayed total FDH activity in homogenates from WT male and female hearts perfused with or without N6022 and monitored NADH absorbance. We detected little FDH activity at baseline in male and female hearts using formaldehyde as a substrate, especially compared with purified FDH enzyme as a positive control (data not shown), but GSNO-R inhibition nonetheless induced a consistent decrease in NADH absorbance ( Figure 5C and 5D) . A similar decrease in NADH absorbance was observed in male and female GSNO-R −/− hearts compared with WT controls, suggesting that GSNO-R inhibition or genetic deletion may impair formaldehyde metabolism in the heart.
Although GSNO and S-hydroxymethylglutathione are the primary substrates of GSNO-R, it is also capable of acting as an ADH. 7 We assayed total ADH activity using isopropanol as a substrate. As a positive control for the assay, we used purified enzyme (data not shown) and total liver homogenate (Online Figure IIB) . Preincubation of mouse liver homogenate with N6022 for 15 minutes had no appreciable effect on total ADH activity in the liver, suggesting that GSNO-R contributes minimally to total liver ADH activity with isopropanol as a substrate. In whole heart homogenates, we detected little activity in WT male and female hearts, and GSNO-R inhibition or genetic deletion had no further effect on total ADH activity in the heart (Online Figure IIC and IID) .
GSNO-R Inhibition Increases Postischemic Free Formaldehyde Levels in Female Hearts
Because N6022 had a significant impact on FDH activity ( Figure 5C and 5D), baseline formaldehyde levels were examined in male and female WT and GSNO-R −/− hearts using a commercially available kit (Sigma-Aldrich). WT female hearts had nearly 2-fold more free formaldehyde at baseline versus WT males ( Figure 6A ). In addition, although male and female GSNO-R −/− hearts had slightly elevated free formaldehyde levels versus WT controls, a 15-minute perfusion with N6022 was not sufficient to acutely increase free formaldehyde levels in either male or female hearts. Postischemic free formaldehyde levels were also assessed, and we no longer detected a difference in free formaldehyde levels between male and female WT hearts ( Figure 6B ). However, free formaldehyde levels were significantly elevated in N6022-treated female hearts and in male and female GSNO-R −/− hearts. N6022-treated male hearts did not Figure 5 . N6022 inhibits S-nitrosoglutathione reductase (GSNO-R) activity in male and female hearts. A through D, GSNO-R activity in whole heart homogenates from control and N6022-treated male and female, wild-type, and GSNO-R −/− hearts measured via nicotinamide adenine dinucleotide (NADH) consumption with GSNO as a substrate (A and B) , and via NADH production with formaldehyde as a substrate (C and D; n=3 hearts/group; *P<0.05 vs control male and **P<0.05 vs control female). November 9, 2018
show an increase in postischemic free formaldehyde compared with non-N6022-treated male hearts. These results suggest that free formaldehyde levels may contribute to the detrimental impact of N6022 treatment during I/R injury in female hearts.
Reactive aldehydes can be produced during I/R injury from lipid peroxidation resulting from elevated ROS. 33 Therefore, we examined 4-hydroxynonenal levels, a marker of lipid peroxidation, to determine if this reaction may be the source of formaldehyde. N6022-treated male hearts and male GSNO-R −/− hearts showed elevated postischemic 4-hydroxynonenal levels compared with control male hearts (Online Figure IIIA and IIIB) . However, postischemic 4-hydroxynonenal levels did not change in N6022-treated female hearts or female GSNO-R −/− hearts (Online Figure IIIA and IIIB). These data suggest that lipid peroxidation is not the source of formaldehyde in the postischemic female heart.
Aldehyde Dehydrogenase 2 Activation Reduces I/R Injury in Female GSNO-R −/− Hearts
We attempted a rescue experiment using Alda-1 to activate mitochondrial aldehyde dehydrogenase 2 (ALDH2), which can metabolize formaldehyde. 34 To determine whether postischemic formaldehyde accumulation contributes to the injury observed in female hearts with GSNO-R ablation, male and female, WT and GSNO-R −/− hearts were perfused with Alda-1 (20 μmol/L) for 10 minutes before the onset of ischemia and for 10 minutes at the start of reperfusion ( Figure 7A ). Alda-1 significantly reduced infarct size in WT male hearts but did not confer an additional infarct-sparing benefit to WT female hearts ( Figure 7B ), which is consistent with prior reports. 27 Nevertheless, Alda-1 significantly reduced infarct size in female GSNO-R −/− hearts ( Figure 7B ), suggesting that excess mitochondrial formaldehyde may exacerbate I/R injury in female hearts with the disruption of GSNO-R. Alda-1 provided no additional benefit to male GSNO-R −/− hearts. Alda-1 also normalized post-I/R formaldehyde levels in male and female GSNO-R −/− hearts (Online Figure IV) .
Formaldehyde Does Not Compete With SNO for the Modification of Common Cysteine Residues
Formaldehyde not only reacts with the amine group on the side chain of lysine, but it can also react with thiols [35] [36] [37] and Figure 6 . S-nitrosoglutathione reductase (GSNO-R) inhibition increases postischemic free formaldehyde levels in female hearts but not in males. A Preischemic and (B) postischemic free formaldehyde levels assessed in control, N6022-treated, and GSNO-R −/− male and female hearts (n=3 hearts/group; *P<0.05 vs wild-type (WT) male and **P<0.05 vs WT female). thus, may compete with SNO for the modification of common cysteine residues. We used a fluorescent maleimide tag to label-free thiols in homogenized hearts treated with the Snitros(yl)ating agent GSNO or formaldehyde to test this hypothesis. As expected, GSNO reduced the fluorescent signal at all concentrations tested in male and female heart homogenates, thus indicating thiol modification ( Figure 8A and 8B) . Formaldehyde treatment did not yield a statistically significant decrease in fluorescence ( Figure 8A and 8C) , suggesting that cysteine may not be the preferred target of formaldehyde. In addition, to determine if GSNO and formaldehyde compete to modify common cysteine residues, we treated samples for 15 minutes with GSNO followed by formaldehyde and vice versa. GSNO significantly suppressed the fluorescent signal in male and female hearts regardless of whether it was applied before or after formaldehyde treatment ( Figure 8D and 8E), suggesting that formaldehyde likely does not directly compete with SNO for the modification of common cysteine residues.
Discussion
Herein we report for the first time that disruption of GSNO-R induces sex-disparate effects during myocardial I/R injury, in part by abrogating sex-dependent protection in females. Although male hearts undoubtedly benefit from N6022-mediated inhibition of GSNO-R during I/R injury, the impact of GSNO-R inhibition on the response to injury in female hearts is clearly detrimental (Figure 1 ). Similar sex-disparate effects were also apparent in hearts from GSNO-R −/− mice using ex vivo and in vivo models of I/R injury (Figure 2) . These results are consistent with prior in vivo work from the male heart, 18, 19 but to our knowledge, are the first to demonstrate that GSNO-R inhibition exacerbates I/R injury in female hearts.
GSNO-R is a major metabolizer of GSNO in the heart, 6 and consistent with the inhibition of GSNO metabolism, we found that N6022 increased total preischemic SNO protein levels, but only in male hearts (Figure 3) . Female hearts exhibited higher baseline SNO protein levels compared with males, which is consistent with our prior studies, 17, 20 but total SNO protein levels remained unchanged with N6022 ( Figure 3) . However, postischemic SNO levels were enhanced in N6022-treated male and female hearts compared with nontreated controls, suggesting that N6022 does affect SNO protein levels in male and female hearts. In addition, we found a strong association between preischemic SNO-ND3 levels (at Cys39) and the degree of I/R injury ( Figure 3C ), such that control female and N6022-treated male hearts showed higher SNO-ND3 levels and less injury, whereas control male and N6022-treated female hearts showed lower SNO-ND3 levels and more injury. SNO at Cys39 of ND3 was reported to reduce postischemic ROS production, 31 and consistent with these results, we found decreased postischemic ROS production in control female and N6022-treated male hearts versus control Figure 8 . Formaldehyde does not compete with S-nitros(yl)ation (SNO) for the modification of common cysteines. A through E, Free thiols were labeled with fluorescent maleimide tags in whole heart homogenates from wild-type males and females before and after treatment with 30, 50, and 100 μmol/L S-nitrosoglutathione (GSNO) or formaldehyde (A through C; n=3-4 hearts/group) or 50 μmol/L GSNO for 15 min, then 50 μmol/L formaldehyde for 15 min, and vice versa (D and E; n=2-3 hearts/group). *P<0.05 vs free thiol male and **P<0.05 vs free thiol female. Note: gel-to-gel variability was normalized with free thiol male sample (MC1). males ( Figure 4) . However, N6022-treated female hearts also showed a reduction in ROS production, which may occur independently from SNO-ND3 levels. Given these results, we investigated the effect of GSNO-R inhibition on its reductase and dehydrogenase functions.
GSNO-R plays a critical role in redox biology by acting as a reductase to regulate reactive nitrogen species and as a dehydrogenase to regulate reactive aldehyde species, all while recycling glutathione and NADH. 38 We performed GSNO-R activity assays to confirm N6022-mediated inhibition of reductase activity in male and female hearts, but unexpectedly found that N6022 significantly impaired GSNO-R-mediated FDH activity ( Figure 5 ). Consistent with this impairment, postischemic formaldehyde levels were increased by nearly 2-fold in N6022-treated female hearts and GSNO-R −/− hearts versus other treatment groups ( Figure 6 ). Taken together, these results suggest that endogenous formaldehyde production may contribute to the pathology of I/R injury. Formaldehyde can be endogenously produced through multiple pathways, including serine oxidation and via demethylation reactions. 39, 40 Serine oxidation by myeloperoxidase may serve as a potential source of formaldehyde during I/R injury. 41 We examined a role for formaldehyde-induced toxicity by using Alda-1 to enhance the activity of ALDH2, which has been shown to play a role in cardioprotection, 27, 42 in part, by metabolizing reactive aldehydes like formaldehyde. 34 Interestingly, we found that Alda-1 reduced infarct size in female GSNO-R −/− hearts (Figure 7 ), further supporting a role for formaldehyde in the pathology of myocardial I/R injury.
Although formaldehyde is a natural byproduct of cellular metabolism, 43 formaldehyde is a reactive electrophile with known toxicological implications. Formaldehyde can form adducts with DNA, lipids, and proteins, 43 in part via the modification of cysteine residues. 35, 44 As such, formaldehyde has the potential to compete with SNO for the modification of cysteines. However, our results suggest that formaldehydeinduced toxicity is likely not occurring through the modification of cysteine residues (Figure 8 ). Overall, our results support a protective mechanism in male hearts whereby the loss of GSNO-R enhances protein SNO levels and decreases postischemic ROS production by increasing SNO-ND3 levels. Female hearts, however, experience increased injury with the loss of GSNO-R, despite a general decrease in postischemic ROS production. This injury likely occurs through the N6022-mediated reduction in SNO-ND3 levels and via the cytotoxic accumulation of formaldehyde.
GSNO-R, I/R Injury, and the Female Heart
Epidemiological studies and preclinical models support the existence of an intrinsic, NO-dependent cardioprotective mechanism in premenopausal female hearts that reduces susceptibility to myocardial I/R injury. 20, [24] [25] [26] In prior studies, we found that WT female hearts exhibited higher levels of phospho-Akt, increased baseline eNOS expression and activation (via Ser1177 phosphorylation), enhanced NO x production, and higher SNO protein levels, which we propose contributes to intrinsic protection from I/R injury. 17, 20 In the current study, we again detect enhanced SNO protein levels at baseline in female hearts (Figure 3 ) and protection from I/R injury versus males (Figure 1 ). We have also found GSNO-R activity to be enhanced at baseline in female hearts versus males, 17, 20 suggesting that GSNO-R plays a protective role in female hearts. Indeed, this seems to be the case, as GSNO-R inhibition or genetic deletion exacerbated I/R injury in female hearts (Figures 1 and 2 ). Although total preischemic SNO protein levels did not change in N6022-treated female hearts (Figure 3) , we did find that SNO-ND3 levels were significantly decreased with N6022 treatment in female hearts (Figure 3) , suggesting that SNO-ND3 may be a critical component of cardioprotection in females that is downregulated with GNSO-R inbition. 45 We also noted that postischemic SNO protein levels were elevated in N6022-treated female hearts, so enhanced SNO of other protein targets may also play a role. Excessive protein SNO has been shown to contribute to disease pathogenesis with neurodegenerative conditions, neuromuscular atrophy, and sepsis. [46] [47] [48] GSNO-R inhibition or genetic deletion in female hearts showed the highest levels of postischemic free formaldehyde ( Figure 6 ), suggesting that formaldehyde may also contribute to the detrimental impact of GSNO-R disruption in female hearts. Formaldehyde is produced endogenously 39, 40 and can be detoxified by GSNO-R. 7 GSNO-R −/− mice also exhibit increased susceptibility to formaldehyde-induced toxicity. 49 ALDH2 is also important for metabolizing formaldehyde and other reactive aldehydes. Lagranha et al 27 suggested that the phosphorylation and activation of ALDH2 contribute to intrinsic cardioprotection in females, and ALDH2 activation with Alda-1 has been shown to reduce ischemic injury in male hearts. 42 Activation of ALDH2 with Alda-1 reduced I/R injury in female GSNO-R −/− hearts, further supporting a role for formaldehyde in I/R injury. Formaldehyde is a reactive electrophile that is cytotoxic and can modify cysteine residues. 35, 44 However, our results suggest that formaldehyde does not directly compete with SNO for the modification of common cysteine residues (Figure 8 ). Nonetheless, formaldehyde seems to be important, yet an unexplored component of I/R injury in female hearts. However, it is not clear why formaldehyde would preferentially affect female hearts (versus males), but female hearts do seem to produce higher baseline levels of formaldehyde ( Figure 6 ), and thus may be more vulnerable to increases in formaldehyde with the loss of GSNO-R.
GSNO-R, I/R Injury, and the Male Heart
Recent work from our group and others has shown that SNO protein levels increase in male hearts with many different forms of cardioprotective stimuli, ranging from ischemic preconditioning and postconditioning to the use of pharmacological agents.
9-15,50-52 These protective effects can be blocked with the SNO-specific reducing agent ascorbate 12 but not with soluble guanylate cyclase or PKG inhibition. 11, [52] [53] [54] Previous studies have reported that the genetic deletion of GSNO-R, which leads to increased myocardial SNO levels, 6, 18, 55 reduced myocardial infarct size in male mice subjected to coronary ligation. 18, 19 In a study by Lima et al, 18 the protection observed in male GSNO-R −/− hearts was attributed to increased capillary density resulting from the SNO-induced, normoxic stabilization of hypoxia-inducible factor 1-α. Our results are in agreement with prior studies as we demonstrate significant cardioprotective effects with the N6022-mediated inhibition or genetic deletion of GSNO-R in WT male hearts subjected to ex vivo and in vivo models of I/R injury (Figures 1 and 2) . Because N6022 increased myocardial SNO protein levels in males (Figure 3) , our results provide further support for the protective role of enhanced SNO protein levels in I/R injury, at least in male hearts. Although Lima et al 18 ultimately concluded that enhanced capillary density was responsible for cardioprotection in male GSNO-R −/− mice, changes in capillary density are unlikely to play a role in our model of protection resulting from acute, ex vivo GSNO-R inhibition. As such, the SNO modification of additional target proteins like ND3 (Figure 3) , may be more important in our model of acute cardioprotection with N6022. With regard to formaldehyde levels in male hearts, we no longer detected a male-female difference in formaldehyde levels after I/R injury (Figure 6 ), suggesting that formaldehyde levels may change during ischemia and the initial minutes of reperfusion. WT male hearts also benefited from ALDH2 activation (Figure 7 ), but it is not clear why elevated formaldehyde levels did not have a detrimental impact on male GSNO-R −/− hearts because formaldehyde levels were elevated ( Figure 6 ). Compensatory adaptation may likely play a role.
Clinical Ramifications of N6022 in the Heart
The results of our studies have important clinical implications. Although a number of pharmacological compounds for inducing cardioprotection have shown great promise in preclinical models of I/R injury, these compounds failed to demonstrate a reduction in infarct size in recent clinical trials. [56] [57] [58] [59] There are a number of factors that may influence the success of these trials, including advanced age in the human population and concurrent pathology, [60] [61] [62] [63] but our results suggest that sex must also be considered when assessing cardioprotective strategies. These results further suggest that different therapeutic strategies may be required to combat ischemic heart disease in males and females. In addition, it is important to note that while most GSNO-R inhibitors are being developed to enhance protein SNO levels, the sex-dependent accumulation of cytotoxic levels of formaldehyde may yield unintended consequences in certain organ systems.
Conclusions
In summary, we demonstrate a novel, sex-dependent role for GSNO-R in myocardial I/R injury. In the male heart, GSNO-R does not seem to be necessary for reducing I/R injury, as GSNO-R inhibition or genetic deletion yielded an improvement in postischemic functional recovery and a reduction in infarct size by enhancing SNO protein levels, namely at Cys39 of ND3, and reducing ROS production at the onset of reperfusion. In female hearts, however, GSNO-R is a requisite for protection, as GSNO-R inhibition reduced postischemic functional recovery and increased infarct size. Although GSNO-R inhibition reduced postischemic ROS production in female hearts, differential changes in protein SNO signaling (ie, reduced SNO at Cys39 of ND3) and increased formaldehyde levels seem to work in tandem to drive injury in female hearts with GSNO-R inhibition. As such, the sex-disparate effects of GSNO-R inhibition provide important mechanistic insight into the regulation of SNO protein and formaldehyde levels during I/R injury in male and female hearts and identify formaldehyde as a novel reactive species in the context of I/R injury. These results further suggest that different strategies may be required for the treatment of ischemic heart disease in males and females.
